Sacituzumab govitecan is effective after several courses of treatment

Sacituzumab govitecan is a drug used to treat certain types of malignant tumors. It is widely used in the treatment of metastatic triple-negative breast cancer (TNBC) and metastatic urothelial carcinoma (mUC). The time it takes for a course of treatment to take effect may vary depending on individual differences. Doctors will judge the duration and effect of treatment based on the patient's specific conditions.

In clinical trials, gosatuzumab is typically administered in consecutive 21-day regimens, with each regimen consisting of twice weekly dosing. According to clinical trial data, approximately 33% of patients with metastatic triple-negative breast cancer experienced a treatment response, including tumor shrinkage or disappearance, after 2 courses of treatment. Among patients with metastatic urothelial cancer, approximately 34% experienced a response after three courses of treatment. Different patients may respond differently to medications. Some patients may experience a treatment response in the early stages after starting a course of treatment, while others may require more courses to see significant results.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.